Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing...

Related Keywords

Taiwan ,Shanghai ,China ,United States ,Hong Kong ,United Kingdom ,Singapore ,Beijing ,Yuanxin ,Shaanxi ,South Korea ,Pakistan ,Chinese ,Eravacycline Xerava ,Jennifer Yang ,Asia Pacific ,Seng Hong Kong ,Kevin Guo ,Kerry Blanchard ,Business Development Updates ,Committee For Human Medicinal Products ,Gilead Sciences Inc ,Hang Seng Indexed Company ,Merck Co Inc ,Yuanxin Group ,China National Medical Products Administration ,Pfizer Inc ,Meditrust Health Co Ltd ,European Medicine Agency ,Sinopharm Group ,Medbanks Health Technology Co Ltd ,Abcellera Biologics Inc ,Department Of Health Hong Kong ,World Health Organization ,Drug Administration ,Health Sciences Authority ,Venatorx Pharmaceuticals ,Tencent Holdings Limited ,Ministry Of Food ,Chief Executive Officer ,Product Highlights ,Reporting Period ,New Drug Application ,Drug Evaluation ,Gilead Sciences ,Biologics License Application ,Drug Safety ,Fast Track Designation ,Orphan Drug Designation ,Taiwan Food ,Rare Severe Disease Priority Review Designation ,Greater China ,Nefigard Phase ,Calliditas Therapeutics ,Human Medicinal Products ,Providence Therapeutics ,Solidarity Trial Vaccines ,Investigational New Drug ,Class One ,Hang Seng Composite Index ,Hang Seng Healthcare Index ,Hang Seng Hong Kong Listed Biotech Index ,Southbound Trading ,Stock Connect Scheme ,Small Cap Index ,Cap Index ,Equity Index ,Small Cap Indexes ,Southeast Asia ,Abcellera Biologics ,Everest Medicines ,Looking Statements ,